The assessment and management of patient-reported outcomes (PROs) is considered secondary to that of cardiometabolic outcomes. When assessed, health-related quality of life (HRQOL), a PRO, can yield pertinent information that cannot be obtained from cardiometabolic assessments. For instance, physical and mental distress can be quantified and treated. Moreover, treatment convenience and satisfaction can be gaged. Behavioral modification, bariatric surgery, and pharmacotherapy can improve PROs. Typically, HRQOL is responsive to changes in weight. Specifically, weight loss and weight gain are associated with positive and negative changes in quality of life, respectively. In addition, patient satisfaction can be influenced by glycemic control. Therefore, hypoglycemia and hyperglycemic episodes can negatively affect patient satisfaction. When managing type 2 diabetes (T2D), it is important to consider how therapies impact PROs. Generally, changes in clinical outcomes mirror changes in PROs. To best manage T2D, integrating the assessment of PROs with clinical outcomes is needed.
Get full access to this article
View all access options for this article.
References
1.
WilliamsED, RawalL, OldenburgBF, et al.Risk of cardiovascular and all-cause mortality: Impact of impaired health-related functioning and diabetes: The Australian Diabetes, Obesity and Lifestyle (AusDiab) study. Diabetes Care, 2012; 35(5):1067–1073; doi: 10.2337/dc11-1288.
2.
BjornerJB, Lyng WoldenM, GundgaardJ, et al.Benchmarks for interpretation of score differences on the SF-36 health survey for patients with diabetes. Value Health, 2013; 16(6):993–1000; doi: 10.1016/j.jval.2013.06.022.
3.
JeongM. Predictors of health-related quality of life in Korean adults with diabetes mellitus. Int J Environ Res Public Health, 2020; 17(23); doi: 10.3390/ijerph17239058.
4.
RedekopWK, KoopmanschapMA, StolkRP, et al.Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care, 2002; 25(3):458–463; doi: 10.2337/diacare.25.3.458.
5.
ZhangX, NorrisSL, ChowdhuryFM, et al.The effects of interventions on health-related quality of life among persons with diabetes: A systematic review. Med Care, 2007; 45(9):820–834; doi: 10.1097/MLR.0b013e3180618b55.
6.
KimH, KimK. Health-related quality-of-life and diabetes self-care activity in elderly patients with diabetes in Korea. J Community Health, 2017; 42(5):998–1007; doi: 10.1007/s10900-017-0347-2.
7.
PatelS, AbreuM, TumyanA, et al.Effect of medication adherence on clinical outcomes in type 2 diabetes: Analysis of the SIMPLE study. BMJ Open Diabetes Res Care, 2019; 7(1):e000761; doi: 10.1136/bmjdrc-2019-000761.
8.
KakoschkeN, ZajacIT, TayJ, et al.Effects of very low-carbohydrate vs. high-carbohydrate weight loss diets on psychological health in adults with obesity and type 2 diabetes: A 2-year randomized controlled trial. Eur J Nutr, 2021; 60:4251–4262; doi: 10.1007/s00394-021-02587-z.
9.
WatsonNA, DyerKA, BuckleyJD, et al.Comparison of two low-fat diets, differing in protein and carbohydrate, on psychological wellbeing in adults with obesity and type 2 diabetes: A randomised clinical trial. Nutr J, 2018; 17(1):62; doi: 10.1186/s12937-018-0367-5.
10.
BrinkworthGD, Luscombe-MarshND, ThompsonCH, et al.Long-term effects of very low-carbohydrate and high-carbohydrate weight-loss diets on psychological health in obese adults with type 2 diabetes: Randomized controlled trial. J Intern Med, 2016; 280(4):388–397; doi: 10.1111/joim.12501.
11.
GuldbrandH, LindströmT, DizdarB, et al.Randomization to a low-carbohydrate diet advice improves health related quality of life compared with a low-fat diet at similar weight-loss in Type 2 diabetes mellitus. Diabetes Res Clin Pract, 2014; 106(2):221–227; doi: 10.1016/j.diabres.2014.08.032.
12.
MyersVH, McVayMA, BrashearMM, et al.Exercise training and quality of life in individuals with type 2 diabetes: A randomized controlled trial. Diabetes Care, 2013; 36(7):1884–1890; doi: 10.2337/dc12-1153.
13.
ReidRD, TullochHE, SigalRJ, et al.Effects of aerobic exercise, resistance exercise or both, on patient-reported health status and well-being in type 2 diabetes mellitus: A randomised trial. Diabetologia, 2010; 53(4):632–640; doi: 10.1007/s00125-009-1631-1.
14.
NicolucciA, BalducciS, CardelliP, et al.Improvement of quality of life with supervised exercise training in subjects with type 2 diabetes mellitus. Arch Intern Med, 2011; 171(21):1951–1953; doi: 10.1001/archinternmed.2011.561.
15.
BaptistaLC, Machado-RodriguesAM, MartinsRA. Exercise but not metformin improves health-related quality of life and mood states in older adults with type 2 diabetes. Eur J Sport Sci, 2017; 17(6):794–804; doi: 10.1080/17461391.2017.1310933.
16.
CaiH, LiG, ZhangP, et al.Effect of exercise on the quality of life in type 2 diabetes mellitus: A systematic review. Qual Life Res, 2017; 26(3):515–530; doi: 10.1007/s11136-016-1481-5.
17.
NicolucciA, BalducciS, CardelliP, et al.Relationship of exercise volume to improvements of quality of life with supervised exercise training in patients with type 2 diabetes in a randomised controlled trial: The Italian Diabetes and Exercise Study (IDES). Diabetologia, 2012; 55(3):579–588; doi: 10.1007/s00125-011-2425-9.
18.
MartinCK, ChurchTS, ThompsonAM, et al.Exercise dose and quality of life: A randomized controlled trial. Arch Intern Med, 2009; 169(3):269–278; doi: 10.1001/archinternmed.2008.545.
19.
DonnellyJE, BlairSN, JakicicJM, et al.American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc, 2009; 41(2):459–471; doi: 10.1249/MSS.0b013e3181949333.
20.
SnelM, SledderingMA, Vd PeijlID, et al.Quality of life in type 2 diabetes mellitus after a very low calorie diet and exercise. Eur J Intern Med, 2012; 23(2):143–149; doi: 10.1016/j.ejim.2011.07.004.
21.
ToobertDJ, GlasgowRE, StryckerLA, et al.Biologic and quality-of-life outcomes from the Mediterranean Lifestyle Program: A randomized clinical trial. Diabetes Care, 2003; 26(8):2288–2293; doi: 10.2337/diacare.26.8.2288.
22.
WolfAM, ConawayMR, CrowtherJQ, et al.Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study. Diabetes Care, 2004; 27(7):1570–1576; doi: 10.2337/diacare.27.7.1570.
23.
MacDonaldCS, NielsenSM, BjørnerJ, et al.One-year intensive lifestyle intervention and improvements in health-related quality of life and mental health in persons with type 2 diabetes: A secondary analysis of the U-TURN randomized controlled trial. BMJ Open Diabetes Res Care, 2021; 9(1); doi: 10.1136/bmjdrc-2020-001840.
24.
WilliamsonDA, RejeskiJ, LangW, et al.Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch Intern Med, 2009; 169(2):163–171; doi: 10.1001/archinternmed.2008.544.
25.
FlorezH, PanQ, AckermannRT, et al.Impact of lifestyle intervention and metformin on health-related quality of life: The diabetes prevention program randomized trial. J Gen Intern Med, 2012; 27(12):1594–1601; doi: 10.1007/s11606-012-2122-5.
26.
KolotkinRL, Gabriel SmolarzB, MeinckeHH, et al.Improvements in health-related quality of life over 3years with liraglutide 3.0mg compared with placebo in participants with overweight or obesity. Clin Obes, 2018; 8(1):1–10; doi: 10.1111/cob.12226.
27.
RuusunenA, VoutilainenS, KarhunenL, et al.How does lifestyle intervention affect depressive symptoms? Results from the Finnish Diabetes Prevention Study. Diabet Med, 2012; 29(7):e126–e132; doi: 10.1111/j.1464-5491.2012.03602.x.
28.
ZhangP, HireD, EspelandMA, et al.Impact of intensive lifestyle intervention on preference-based quality of life in type 2 diabetes: Results from the Look AHEAD trial. Obesity (Silver Spring), 2016; 24(4):856–864; doi: 10.1002/oby.21445.
29.
RubinRR, WaddenTA, BahnsonJL, et al.Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: The Look AHEAD Trial. Diabetes Care, 2014; 37(6):1544–1553; doi: 10.2337/dc13-1928.
30.
WaddenT, BantleJ, BlackburnG, et al.Eight-year weight losses with an intensive lifestyle intervention: The look AHEAD study. Obesity (Silver Spring), 2014; 22(1):5–13; doi: 10.1002/oby.20662.
31.
PriceDW, MaY, RubinRR, et al.Depression as a predictor of weight regain among successful weight losers in the diabetes prevention program. Diabetes Care, 2013; 36(2):216–221; doi: 10.2337/dc12-0293.
32.
GiletH, GruenbergerJB, BaderG, et al.Demonstrating the burden of hypoglycemia on patients' quality of life in diabetes clinical trials: Measurement considerations for hypoglycemia. Value Health, 2012; 15(8):1036–1041; doi: 10.1016/j.jval.2012.06.002.
33.
IshiiH, AndersonJHJr., YamamuraA, et al.Improvement of glycemic control and quality-of-life by insulin lispro therapy: Assessing benefits by ITR-QOL questionnaires. Diabetes Res Clin Pract, 2008; 81(2):169–178; doi: 10.1016/j.diabres.2008.03.020.
34.
HermanWH, IlagLL, JohnsonSL, et al.A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care, 2005; 28(7):1568–1573; doi: 10.2337/diacare.28.7.1568.
35.
KhuntiK, WoldenML, ThorstedBL, et al.Clinical inertia in people with type 2 diabetes: A retrospective cohort study of more than 80,000 people. Diabetes Care, 2013; 36(11):3411–3417; doi: 10.2337/dc13-0331.
36.
PfeifferKM, BasseA, LeeXY, et al.Diabetes management and healthcare resource use when intensifying from basal insulin to basal-bolus: A survey of type 2 diabetes patients. Diabetes Ther, 2018; 9(5):1931–1944; doi: 10.1007/s13300-018-0487-0.
37.
van der DoesFE, de NeelingJN, SnoekFJ, et al.Randomized study of two different target levels of glycemic control within the acceptable range in type 2 diabetes. Effects on well-being at 1year. Diabetes Care, 1998; 21(12):2085–2093; doi: 10.2337/diacare.21.12.2085.
38.
PolonskyWH, ThompsonS, WeiW, et al.Greater fear of hypoglycaemia with premixed insulin than with basal-bolus insulin glargine and glulisine: Patient-reported outcomes from a 60-week randomised study. Diabetes Obes Metab, 2014; 16(11):1121–1127; doi: 10.1111/dom.12328.
39.
RiddleMC, RosenstockJ, VlajnicA, et al.Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: Twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes Metab, 2014; 16(5):396–402; doi: 10.1111/dom.12225.
40.
BlondeL, JendleJ, GrossJ, et al.Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): A randomised, open-label, phase 3, non-inferiority study. Lancet, 2015; 385(9982):2057–2066; doi: 10.1016/s0140-6736(15)60936-9.
41.
ChengQ, YangS, ZhaoC, et al.Efficacy of metformin-based oral antidiabetic drugs is not inferior to insulin glargine in newly diagnosed type 2 diabetic patients with severe hyperglycemia after short-term intensive insulin therapy. J Diabetes, 2015; 7(2):182–191; doi: 10.1111/1753-0407.12167.
42.
EmeryA, YeC, ChoiH, et al.Intermittent intensive insulin therapy for type 2 diabetes: Effects on hypoglycemia, weight gain, and quality of life over 2 years. Endocr Pract, 2019; 25(9):899–907; doi: 10.4158/ep-2019-0111.
43.
UshakovaO, SokolovskayaV, MorozovaA, et al.Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: A 16-week, randomized, open-label, parallel-group trial conducted in russia. Clin Ther, 2007; 29(11):2374–2384; doi: 10.1016/j.clinthera.2007.11.017.
44.
HouldenR, RossS, HarrisS, et al.Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of type 2 diabetes: The Canadian INSIGHT Study. Diabetes Res Clin Pract, 2007; 78(2):254–258; doi: 10.1016/j.diabres.2007.03.021.
45.
VinikAI, ZhangQ. Adding insulin glargine versus rosiglitazone: Health-related quality-of-life impact in type 2 diabetes. Diabetes Care, 2007; 30(4):795–800; doi: 10.2337/dc06-1712.
46.
Secnik BoyeK, MatzaLS, OglesbyA, et al.Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes, 2006; 4:80; doi: 10.1186/1477-7525-4-80.
47.
ChenJ, FanL, PengX, et al.Patient-reported outcomes in a study of human regular U-500 insulin delivered by continuous subcutaneous insulin infusion or multiple daily injections in patients with type 2 diabetes. Diabetes Obes Metab, 2021; 23(1):240–244; doi: 10.1111/dom.14191.
48.
RaskinP, BodeBW, MarksJB, et al.Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: A randomized, parallel-group, 24-week study. Diabetes Care, 2003; 26(9):2598–2603; doi: 10.2337/diacare.26.9.2598.
49.
GrunbergerG, BhargavaA, LyT, et al.Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study. Diabetes Obes Metab, 2020; 22(3):434–441; doi: 10.1111/dom.13947.
50.
VigerskyRA, HuangS, CorderoTL, et al.Improved HBA1C, total daily insulin dose, and treatment satisfaction with insulin pump therapy compared to multiple daily insulin injections in patients with type 2 diabetes irrespective of baseline C-peptide levels. Endocr Pract, 2018; 24(5):446–452; doi: 10.4158/ep-2017-0234.
51.
WainsteinJ, MetzgerM, BoazM, et al.Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients. Diabet Med, 2005; 22(8):1037–1046; doi: 10.1111/j.1464-5491.2005.01597.x.
52.
ReznikY, CohenO, AronsonR, et al.Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): A randomised open-label controlled trial. Lancet, 2014; 384(9950):1265–1272; doi: 10.1016/s0140-6736(14)61037-0.
53.
PeyrotM, BarnettAH, MeneghiniLF, et al.Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab, 2012; 14(12):1081–1087; doi: 10.1111/j.1463-1326.2012.01636.x.
54.
ParknerT, LaursenT, VestergaardET, et al.Insulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long-acting insulin in type 2 diabetes. Diabet Med, 2008; 25(5):585–591; doi: 10.1111/j.1464-5491.2008.02418.x.
55.
BergenstalRM, PeyrotM, DreonDM, et al.Implementation of basal-bolus therapy in type 2 diabetes: A randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. Diabetes Technol Ther, 2019; 21(5):273–285; doi: 10.1089/dia.2018.0298.
56.
LingvayI, Pérez ManghiF, García-HernándezP, et al.Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: The DUAL V randomized clinical trial. JAMA, 2016; 315(9):898–907; doi: 10.1001/jama.2016.1252.
57.
MiyaA, NakamuraA, MiyoshiH, et al.Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial. J Diabetes Investig, 2018; 9(1):119–126; doi: 10.1111/jdi.12654.
58.
AbreuM, TumyanA, ElhassanA, et al.A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study. Diabetes Obes Metab, 2019; 21(9):2133–2141; doi: 10.1111/dom.13794.
59.
VanderheidenA, HarrisonL, WarshauerJ, et al.Effect of adding liraglutide vs placebo to a high-dose lnsulin regimen in patients with type 2 diabetes: A randomized clinical trial. JAMA Intern Med, 2016; 176(7):939–947; doi: 10.1001/jamainternmed.2016.1540.
60.
SchmidtWE, ChristiansenJS, HammerM, et al.Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: Results from a randomized, open-label study. Diabet Med, 2011; 28(6):715–723; doi: 10.1111/j.1464-5491.2011.03276.x.
61.
DunganKM, PovedanoST, ForstT, et al.Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): A randomised, open-label, phase 3, non-inferiority trial. Lancet, 2014; 384(9951):1349–1357; doi: 10.1016/s0140-6736(14)60976-4.
62.
BestJH, BoyeKS, RubinRR, et al.Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med, 2009; 26(7):722–728; doi: 10.1111/j.1464-5491.2009.02752.x.
63.
GiorginoF, BenroubiM, SunJH, et al.Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care, 2015; 38(12):2241–2249; doi: 10.2337/dc14-1625.
64.
ArodaVR, BainSC, CariouB, et al.Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): A randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol, 2017; 5(5):355–366; doi: 10.1016/s2213-8587(17)30085-2.
65.
DiamantM, Van GaalL, GuerciB, et al.Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol, 2014; 2(6):464–473; doi: 10.1016/s2213-8587(14)70029-4.
66.
DiamantM, NauckMA, ShaginianR, et al.Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care, 2014; 37(10):2763–2773; doi: 10.2337/dc14-0876.
67.
RosenstockJ, NinoA, SofferJ, et al.Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: A randomized trial. Diabetes Care, 2020; 43(10):2509–2518; doi: 10.2337/dc19-2316.
68.
YangCY, ChenYR, OuHT, et al.Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: A real-world study and systematic review. Cardiovasc Diabetol, 2021; 20(1):21; doi: 10.1186/s12933-020-01211-4.
69.
YuM, Van BruntK, VarnadoOJ, et al.Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: Data from the AWARD phase III clinical trial programme. Diabetes Obes Metab, 2016; 18(4):419–424; doi: 10.1111/dom.12624.
70.
Russell-JonesD, CuddihyRM, HanefeldM, et al.Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study. Diabetes Care, 2012; 35(2):252–258; doi: 10.2337/dc11-1107.
71.
McGuireDK, ShihWJ, CosentinoF, et al.Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis. JAMA Cardiol, 2021; 6(2):148–158; doi: 10.1001/jamacardio.2020.4511.
72.
ZinmanB, WannerC, LachinJM, et al.Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015; 373(22):2117–2128; doi: 10.1056/NEJMoa1504720.
73.
KansalA, ReifsniderOS, ProskorovskyI, et al.Cost-effectiveness analysis of empagliflozin treatment in people with type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial. Diabet Med, 2019; 36(11):1494–1502; doi: 10.1111/dme.14076.
74.
ButlerJ, AnkerSD, FilippatosG, et al.Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: The EMPEROR-reduced trial. Eur Heart J, 2021; 42(13):1203–1212; doi: 10.1093/eurheartj/ehaa1007.
75.
NassifME, WindsorSL, TangF, et al.Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: The DEFINE-HF trial. Circulation, 2019; 140(18):1463–1476; doi: 10.1161/circulationaha.119.042929.
76.
GrandyS, LangkildeAM, SuggJE, et al.Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2years. Int J Clin Pract, 2014; 68(4):486–494; doi: 10.1111/ijcp.12341.
77.
GrandyS, SternhufvudC, RydenA, et al.Patient-reported outcomes among patients with type 2 diabetes mellitus treated with dapagliflozin in a triple-therapy regimen for 52weeks. Diabetes Obes Metab, 2016; 18(3):306–309; doi: 10.1111/dom.12604.
78.
IshiiH, NakajimaH, KameiN, et al.Quality-of-life comparison of dapagliflozin versus dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes mellitus: A randomized controlled trial (J-BOND Study). Diabetes Ther, 2020; 11(12):2959–2977; doi: 10.1007/s13300-020-00941-8.
79.
CaiJ, DelahantyLM, AkapameS, et al.Impact of canagliflozin treatment on health-related quality of life among people with type 2 diabetes mellitus: A pooled analysis of patient-reported outcomes from randomized controlled trials. Patient, 2018; 11(3):341–352; doi: 10.1007/s40271-017-0290-4.
80.
PeyrotM, RubinRR. How does treatment satisfaction work?: Modeling determinants of treatment satisfaction and preference. Diabetes Care, 2009; 32(8):1411–1417; doi: 10.2337/dc08-2256.
81.
GrandyS, HashemiM, LangkildeAM, et al.Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab, 2014; 16(7):645–650; doi: 10.1111/dom.12263.
82.
JódarE, MichelsenM, PolonskyW, et al.Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6). Diabetes Obes Metab, 2020; 22(8):1339–1347; doi: 10.1111/dom.14039.
83.
IshiiH, NiiyaT, OnoY, et al.Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: The PAGE1 study. Diabetol Metab Syndr, 2017; 9:3; doi: 10.1186/s13098-016-0202-0.
84.
FarmerAJ, OkeJ, StevensR, et al.Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes. Diabetes Obes Metab, 2011; 13(12):1136–1141; doi: 10.1111/j.1463-1326.2011.01475.x.
85.
KheniserK, AminianA, KashyapS. A review of the current evidence: Impact of metabolic surgery on diabetes outcomes and obesity-associated macrovascular complications. Curr Diabetes Reports, 2020; 20(11):57; doi: 10.1007/s11892-020-01350-8.
86.
GrandyS, FoxKM. Change in health status (EQ-5D) over 5years among individuals with and without type 2 diabetes mellitus in the SHIELD longitudinal study. Health Qual Life Outcomes, 2012; 10:99; doi: 10.1186/1477-7525-10-99.
87.
HayesA, ArimaH, WoodwardM, et al.Changes in quality of life associated with complications of diabetes: Results from the ADVANCE study. Value Health, 2016; 19(1):36–41; doi: 10.1016/j.jval.2015.10.010.
88.
BriggsAH, BhattDL, SciricaBM, et al.Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. Diabetes Res Clin Pract, 2017; 130:24–33; doi: 10.1016/j.diabres.2016.12.019.
89.
CohenRV, PereiraTV, AboudCM, et al.Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity: A randomized clinical trial. JAMA Surg, 2020; 155(8):e200420; doi: 10.1001/jamasurg.2020.0420.
90.
WentworthJM, PlayfairJ, LaurieC, et al.Multidisciplinary diabetes care with and without bariatric surgery in overweight people: A randomised controlled trial. Lancet Diabetes Endocrinol, 2014; 2(7):545–552; doi: 10.1016/s2213-8587(14)70066-x.
91.
DingSA, SimonsonDC, WewalkaM, et al.Adjustable gastric band surgery or medical management in patients with type 2 diabetes: A randomized clinical trial. J Clin Endocrinol Metab, 2015; 100(7):2546–2556; doi: 10.1210/jc.2015-1443.
92.
SimonsonDC, VernonA, FosterK, et al.Adjustable gastric band surgery or medical management in patients with type 2 diabetes and obesity: Three-year results of a randomized trial. Surg Obes Relat Dis, 2019; 15(12):2052–2059; doi: 10.1016/j.soard.2019.03.038.
93.
SimonsonDC, HalperinF, FosterK, et al.Clinical and patient-centered outcomes in obese patients with type 2 diabetes 3 years after randomization to Roux-en-Y gastric bypass surgery versus intensive lifestyle management: The SLIMM-T2D Study. Diabetes Care, 2018; 41(4):670–679; doi: 10.2337/dc17-0487.
94.
HalperinF, DingSA, SimonsonDC, et al.Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: Feasibility and 1-year results of a randomized clinical trial. JAMA Surg, 2014; 149(7):716–726; doi: 10.1001/jamasurg.2014.514.
95.
AminianA, KashyapSR, WolskiKE, et al.Patient reported outcomes after metabolic surgery versus medical therapy for diabetes: Insights from the STAMPEDE randomized trial. Ann Surg, 2021; 274(3):524–532; doi: 10.1097/sla.0000000000005003.
96.
SchauerP, BhattD, KirwanJ, et al.Bariatric surgery versus intensive medical therapy for diabetes -5-year outcomes. N Engl J Med, 2017; 376(7):641–651; doi: 10.1056/NEJMoa1200225.
97.
MingroneG, PanunziS, De GaetanoA, et al.Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5year follow-up of an open-label, single-centre, randomised controlled trial. Lancet, 2015; 386(9997):964–973; doi: 10.1016/s0140-6736(15)00075-6.
98.
MingroneG, PanunziS, De GaetanoA, et al.Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet, 2021; 397(10271):293–304; doi: 10.1016/s0140-6736(20)32649-0.
99.
KarlssonJ, TaftC, RydénA, et al.Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: The SOS intervention study. Int J Obes (Lond), 2007; 31(8):1248–1261; doi: 10.1038/sj.ijo.0803573.
100.
O'BrienPE, DixonJB, LaurieC, et al.Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: A randomized trial. Ann Intern Med, 2006; 144(9):625–633; doi: 10.7326/0003-4819-144-9-200605020-00005.
101.
AdamsTD, DavidsonLE, LitwinSE, et al.Health benefits of gastric bypass surgery after 6years. JAMA, 2012; 308(11):1122–1131; doi: 10.1001/2012.jama.11164.
102.
KolotkinRL, DavidsonLE, CrosbyRD, et al.Six-year changes in health-related quality of life in gastric bypass patients versus obese comparison groups. Surg Obes Relat Dis, 2012; 8(5):625–633; doi: 10.1016/j.soard.2012.01.011.
103.
GrönroosS, HelmiöM, JuutiA, et al.Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss and quality of life at 7 years in patients with morbid obesity: The SLEEVEPASS randomized clinical trial. JAMA Surg, 2021; 156(2):137–146; doi: 10.1001/jamasurg.2020.5666.
104.
CastanedaD, PopovVB, WanderP, et al.Risk of suicide and self-harm is increased after bariatric surgery-a systematic review and meta-analysis. Obes Surg, 2019; 29(1):322–333; doi: 10.1007/s11695-018-3493-4.
105.
SzmulewiczA, WanisKN, GripperA, et al.Mental health quality of life after bariatric surgery: A systematic review and meta-analysis of randomized clinical trials. Clin Obes, 2019; 9(1):e12290; doi: 10.1111/cob.12290.
106.
SalminenP, HelmiöM, OvaskaJ, et al.Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: The SLEEVEPASS randomized clinical trial. JAMA, 2018; 319(3):241–254; doi: 10.1001/jama.2017.20313.
107.
RisstadH, SøvikTT, EngströmM, et al.Five-year outcomes after laparoscopic gastric bypass and laparoscopic duodenal switch in patients with body mass index of 50 to 60: A randomized clinical trial. JAMA Surg, 2015; 150(4):352–361; doi: 10.1001/jamasurg.2014.3579.
108.
NguyenNT, KimE, VuS, et al.Ten-year outcomes of a prospective randomized trial of laparoscopic gastric bypass versus laparoscopic gastric banding. Ann Surg, 2018; 268(1):106–113; doi: 10.1097/sla.0000000000002348.
109.
NavariniD, MadalossoCAS, TognonAP, et al.Predictive factors of gastroesophageal reflux disease in bariatric surgery: A controlled trial comparing sleeve gastrectomy with gastric bypass. Obes Surg, 2020; 30(4):1360–1367; doi: 10.1007/s11695-019-04286-5.
110.
FelsenreichDM, PragerG, KefurtR, et al.Quality of life 10 years after sleeve gastrectomy: A multicenter study. Obesity Facts, 2019; 12(2):157–166; doi: 10.1159/000496296.
111.
PeterliR, WölnerhanssenBK, PetersT, et al.Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: The SM-BOSS randomized clinical trial. JAMA, 2018; 319(3):255–265; doi: 10.1001/jama.2017.20897.
112.
BiterLU, van BuurenMMA, MannaertsGHH, et al.Quality of life 1 year after laparoscopic sleeve gastrectomy versus laparoscopic Roux-en-Y gastric bypass: A randomized controlled trial focusing on gastroesophageal reflux disease. Obes Surg, 2017; 27(10):2557–2565; doi: 10.1007/s11695-017-2688-4.
113.
BatsisJA, Lopez-JimenezF, Collazo-ClavellML, et al.Quality of life after bariatric surgery: A population-based cohort study. Am J Med, 2009; 122(11):1055.e1051–e1055.e1010; doi: 10.1016/j.amjmed.2009.05.024.
114.
FløloTN, TellGS, KolotkinRL, et al.Changes in quality of life 5years after sleeve gastrectomy: A prospective cohort study. BMJ Open, 2019; 9(9):e031170; doi: 10.1136/bmjopen-2019-031170.
115.
WarkentinLM, DasD, MajumdarSR, et al.The effect of weight loss on health-related quality of life: Systematic review and meta-analysis of randomized trials. Obes Rev, 2014; 15(3):169–182; doi: 10.1111/obr.12113.
116.
AckermannRT, EdelsteinSL, NarayanKM, et al.Changes in health state utilities with changes in body mass in the Diabetes Prevention Program. Obesity (Silver Spring), 2009; 17(12):2176–2181; doi: 10.1038/oby.2009.114.
117.
MagkosF, FraterrigoG, YoshinoJ, et al.Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab, 2016; 23(4):591–601; doi: 10.1016/j.cmet.2016.02.005.
118.
MessierSP, MihalkoSL, LegaultC, et al.Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: The IDEA randomized clinical trial. JAMA, 2013; 310(12):1263–1273; doi: 10.1001/jama.2013.277669.
119.
DainelliL, LuoDR, CohenSS, et al.Health-related quality of life in weight loss interventions: Results from the OPTIWIN trial. Int J Environ Res Public Health, 2021; 18(4); doi: 10.3390/ijerph18041785.
